Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C Patients
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2016-12-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 19
- Registration Number
- NCT02118597
A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis
- Conditions
- Wegener's Granulomatosis or Microscopic Polyangiitis
- Interventions
- First Posted Date
- 2014-04-16
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 30
- Registration Number
- NCT02115997
- Locations
- 🇮🇳
Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute; Department of Rheumatologz, Mumbai, Maharashtra, India
🇮🇳St. John's Medical College Hospital; Rheumatology, Bangalore, India
🇮🇳Medanta-The Medicity, Gurgaon, Haryana, India
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
- First Posted Date
- 2014-04-09
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 310
- Registration Number
- NCT02108652
- Locations
- 🇺🇸
Mayo Clinic Cancer Center, Jacksonville, Florida, United States
🇺🇸Stanford Cancer Center, Stanford, California, United States
🇺🇸Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States
Observational Study Evaluating the Quality of Pegylated Interferon Alfa-2a and Ribavirin Treatment for Chronic Hepatitis C in Cooperation With the BNG (Association of German Resident Gastroenterologists)
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 10228
- Registration Number
- NCT02106156
European, Open-label, Prospective, Multinational, Multicenter Study in Adult Subjects With Type 1 or Type 2 Diabetes Previously on MDI or CSII Therapy. Subjects Home Setting is Considered Routine Practice.
- Conditions
- Type 2 Diabetes, Type 1 Diabetes
- Interventions
- Device: Accu-Chek® Insight Insulin Pump
- First Posted Date
- 2014-04-07
- Last Posted Date
- 2016-09-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 80
- Registration Number
- NCT02105103
A 2-Part Study to Evaluate the Safety of Supra-Therapeutic Doses of RO4602522 and to Investigate the Effect of RO4602522 on the QTc Interval
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2014-04-04
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 203
- Registration Number
- NCT02104648
A Study Evaluating the Perception of Insertion Pain With Accu-Chek FlexLink and FlexLink Plus Insulin Pump Devices Under Real Life Conditions in Diabetic Patients.
- Conditions
- Diabetes Mellitus Type 2, Diabetes Mellitus Type 1
- Interventions
- Device: Accu-Chek FlexLinkDevice: Accu-Chek FlexLink Plus
- First Posted Date
- 2014-04-04
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 80
- Registration Number
- NCT02103595
A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2014-04-04
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 313
- Registration Number
- NCT02104674
Multicenter, Post-marketing, Non-interventional, Observational Study in RA Patients Treated With RoActemra/Actemra (Tocilizumab)
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2014-04-02
- Last Posted Date
- 2017-12-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 400
- Registration Number
- NCT02101307
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
🇨🇳West China Hospital, Sichuan University, Chengdu, China
🇨🇳Sichuan Provincial People's Hospital, Chengdu, China
A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: EtrozulimabDrug: Placebo
- First Posted Date
- 2014-04-01
- Last Posted Date
- 2021-08-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 609
- Registration Number
- NCT02100696
- Locations
- 🇺🇸
Louisiana Research Center, LLC, Shreveport, Louisiana, United States
🇧🇪CHU de Liège; Tour de Pathologie, Liège, Belgium
🇺🇸Gastroenterology Center of the Midsouth, P.C., Memphis, Tennessee, United States